

## **Abstract**

### **The using of the inhibitors glycoprotein IIb/IIIa receptors in patient with acute coronary syndrom.**

Mgr.Iva Vaňková

Katedra farmakologie a toxikologie

Farmaceutická fakulta Hradec Králové, Univerzita Karlova v Praze

The experimental part Katlab and Koronary unit Nemocnice Na Homolce Praha

The rigorous work is bent on problems using antiagregans in patients with acute coronary syndrom, especially subset of those high risk patients, who had to subject achievement PCI (percutaneous coronary intervention).

The aim was to compare matters from insider inhibitors glycoprotein receptors IIb/IIIa, in the concrete abciximab and eptifibatid, and on the basis observed result evaluate contribution in treatment inmate acute coronary syndrom.

Near tracked inmates appraised data from 4 groups parameters, which brightly determine quality treatment. Necessity repeat achievement PCI to the 48 throw, death inmate to the 30 days, intricate bleeding, time hospitalization.

Data are present in well-arranged tables.

On the basis detailed evaluation mutual juxtaposition data of both effective materials it is possible state, as though both matters are four-square contribution in treatment inmates with acute coronary syndrom, however wasn't found no significant differences in quality and results treatment.